Recent discussions on X about Ginkgo Bioworks (DNA) have centered around the company's latest product developments and upcoming financial results. Posts highlight excitement over the launch of a new reagent product, specifically a cell-free protein synthesis system, which some see as a significant step forward for the synthetic biology leader. There’s also anticipation building around the upcoming Q2 earnings, with users speculating on potential growth in biofoundry services.
While enthusiasm exists, there’s a notable undercurrent of caution among participants on the platform. Some express concern over the stock’s volatility and historical challenges, with a few pointing to past criticisms of the company’s business model. The conversation reflects a polarized view, with both optimism for innovation and skepticism about long-term stability driving engagement.
Note: This discussion summary was generated from an AI condensation of post data.
Ginkgo Bioworks Insider Trading Activity
Ginkgo Bioworks insiders have traded $DNA stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $DNA stock by insiders over the last 6 months:
- MARK E. DMYTRUK (See remarks) has made 0 purchases and 4 sales selling 3,480 shares for an estimated $30,465.
- STEVEN P. COEN (See remarks) has made 0 purchases and 5 sales selling 3,189 shares for an estimated $28,539.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Ginkgo Bioworks Hedge Fund Activity
We have seen 1 institutional investors add shares of Ginkgo Bioworks stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPL WEALTH MANAGEMENT, LLC added 10,000 shares (+inf%) to their portfolio in Q1 2025, for an estimated $57,000
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Ginkgo Bioworks Government Contracts
We have seen $120,084,477 of award payments to $DNA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- TRAVELER-BASED GENOMIC SURVEILLANCE: $54,930,849
- TRAVELER-BASED GENOMIC SURVEILLANCE PROGRAM: $53,725,682
- AIRPORT GENOMIC TESTING: $7,774,961
- TEST SURGE AND DATA SHARING MULTIPLE AWARD IDIQ: $1,236,101
- DARPA ICE CONTROL FOR COLD ENVIRONMENTS (ICE): $1,191,941
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
